Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05402839

Screening of Malignant Hyperthermia Susceptible Individuals

This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.

Recruiting

Interested in participating?

Request Info

Key information

Age range

0 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

Location status: Recruiting

Location contact

Yang Zhou, M.D.

SUB_INVESTIGATOR

Yinyin Qu, M.D.

CONTACT

[email protected]

+8613466759889

Yinyin Qu, M.D.

SUB_INVESTIGATOR

Yongzheng Han, M.D.

SUB_INVESTIGATOR

Zhengqian Li, Ph.D., M.D.

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing surgery under general anesthesia during the study period developed malignant hyperthermia during or after surgery.

Exclusion criteria

  • Malignant hyperthermia was ruled out by later treatment and diagnosis;
  • The patient or family member refuses to be recruited.

Treatment and study plan

Primary outcomes

  1. Whole exome sequencing

    Time frame: immediately after MH was diagnosed

Study contacts

Contact information is provided by the study sponsor or research team.

Yinyin Qu, M.D.

CONTACT

[email protected]

+8613466759889

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

Molecular Genetics Study on Screening of Malignant Hyperthermia Susceptible Individuals

Important dates

Study start
2022
Primary completion
2041
Study completion
2041
First posted
Jun 2, 2022
Registry last updated
Jun 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.